The immune checkpoints, such as PD-1, PD-L1, CTLA-4, and TIM-3, play an important role in the emerging biomarkers of B-ALL, including disease diagnosis, severity/activity evaluation, or disease outcome prediction. This evidence concerns the gene CTLA4 and precursor B-cell acute lymphoblastic leukemia.